Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Tests Preemptively Screen Drug Resistant Bacteria

By LabMedica International staff writers
Posted on 31 May 2012
Rapid diagnostic testing (RDT) can be used to screen carriers of suspected methicillin-resistant Staphylococcus aureus (MRSA) in hospitals. More...


Preemptive isolation of suspected MRSA carriers is a cornerstone of successful MRSA control policies but is hampered when using conventional cultures with diagnostic delays of three to five days, as many noncarriers remain unnecessarily isolated.

Scientists at the University Medical Center (Utrecht, The Netherlands) investigated whether RDT reduces the amount of unnecessary isolation days, the costs, and benefits in intensive care units (ICUs) in a multicenter hospital-wide study. The effects of RDT of MRSA was evaluated using polymerase chain reaction (PCR) assays added to screening with conventional microbiological culture methods for patients eligible for MRSA screening. Two real time PCR assays were subsequently evaluated: BD GeneOhm MRSA PCR between December 2005 and May 2007, and Xpert MRSA assay between April 2007 and June 2008.

A total of 163 patients at risk for MRSA carriage were screened and MRSA prevalence was 3.1%. Duration of isolation was 27.6 hours with BD GeneOhm MRSA PCR (previously known as IDI-MRSA, BD Diagnostics, San Diego, CA, USA) and 21.4 hours with GeneXpert (Cepheid, Sunnyvale, CA, USA), and would have been 96 hours when based on conventional cultures. The negative predictive value was 100% for both tests.

Numbers of isolation days were reduced by 44.3% with PCR-based screening at the additional costs of EUR 327.84 for the BD assay and EUR 252.14 for the GeneXpert test per patient screened. Costs per isolation day avoided were calculated to be EUR 136.04 for the BD assay and EUR 121.76 for the GeneXpert. The authors concluded therefore that in a low endemic setting for MRSA, RDT safely reduced the number of unnecessary isolation days.

The platforms used are not suited for the large volumes of multiple tests in a short period of time, as only 16 could be performed simultaneously on Cepheid's Smartcycler and four tests on the GeneXpert systems. This endorses the need for large volume testing or pooling of swabs in ICU patients to decrease unnecessary preemptive isolation time. Another option would be to use chromogenic agar-based screening, which has a slightly longer turn around time in the laboratory, but can be performed in large volumes and is easily implemented in routine laboratory practice, including weekends. The study was originally published on February 7, 2012, in the journal Critical Care.

Related Links:
University Medical Center Utrecht
BD Diagnostics
Cepheid


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.